(CercleFinance.com) – Pfizer announces that it has launched a phase 2/3 study, EPIC-PEDS, to evaluate the safety, pharmacokinetics and efficacy of Paxlovid in non-hospitalized children with Covid-19 and symptomatic, who are at risk of progression to serious disease.
This open-label, multicenter, single-arm study will enroll approximately 140 participants between the ages of six and 17, divided into two cohorts. An independent data monitoring committee will review participants’ safety data.
Paxlovid is currently authorized in the United States under FDA Emergency Use Authorization in high-risk adult patients and high-risk pediatric patients 12 years of age and older weighing at least 40 kg.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
